A*Star

The first assay to be developed under the new five-year strategic partnership is a solid biopsy breast cancer assay designed to guide drug selection.

Each panel that the collaborators develop is expected to be highly multiplexed and syndromic, addressing clinically important infectious diseases in Asia.

GUSTO study researchers said maternal lifestyle, fetal genetic, and fetal epigenetic factors affect birth weight and early childhood adiposity.

While gain-of-function mutations lead to congenital arhinia, inactivating mutations lead to an adult-onset muscular dystrophy, the researchers reported.

The partners will collaborate in developing Atreca's single-cell sequencing technology to advance new cancer immunotherapies.

Members of the Genome 10K Consortium sequenced the genome of the ocean sunfish, Mola mola, comparing it to sequences from pufferfish and other related species.

The mass spectrometry instrument maker will provide A*Star's Bioprocessing Technology Institute with expertise and access to a Synapt G2-S instrument.

Singapore plans to spend $13.2 billion on research and development between 2016 and 2020.

The partners will focus on sequencing and analyzing bacteria and viruses that cause a number of diseases as well as those that make up human microbiomes.

The collaboration will further develop Agilent's AssayMAP Bravo platform to bridge gaps in analytical tests and standards for glycoprotein-based drugs. 

Pages

The president of France's National Research Agency has resigned, according to Nature News.

A senator wants a "right-to-try" provision in the US Food and Drug Administration funding bill, but an ethicist says at Stat News that it would undermine the role of clinical trials.

The Guardian's Barbara Ellen has tried out some DNA testing services to see whether they provide valuable information.

In PNAS this week: red algae Porphyra umbicalis genome, deep neural network model for sequencing peptides, and more.